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~ U s s  of a Percutaneous Trensvalvar Axial Pump 
for Left Ventdcular Assistance During High Risk 
Angioplasty 
Philip Urban, Pascal Chatelain, Jean Pierre Ki[=isch, Emmanuel Moraedini, 
Vifali Verine, W~lhelm Rutishauser. University Hospital, Geneva, Switzerland 
Po~: left ventficular function is a dsk factor for major complications during 
PTCA. We used a now 14 French transvaivar pump system (Hemopump ,,R 
Medtrontc DLP) to support LV function during PTCA in 8 patients. 
Mean patient age was 71 :E 8 years, 5 (63%) were woman, median LVEF 
was 29% (17-67%), and all had multivessa! disease and class ifi or IV angina. 
Median heart failure class was II (I to IV). After successful percutaneous 
placement of the hemopump in all cases, maen wedge pressure dropped 
from 18 :E 8 to 15 =i: 9 mmHg (p < 0.05) and mean CI rose from 2.0 :t: 0.2 to 
2.3 ± 0.4 I/miNm2 (NS). Target vessels were 1 unprotected left main stem, 7 
native coronary branches, and 4 vein grefts. Stent implantation was used in 3 
patients. Pump function was lifesaving on two occasions (Isshemla-induced 
EMD in one oaso, and air embolism due to balloon rupture in another,L 
After a median of 2 hours (range 1 to 6 hours), the pump and introducer were 
reldeved, and hemostaais was obtained by extemal compression. There was 
no in-hospital death, myocardial infarction, need for CABG, major hematoma, 
or significant hemolysis. Two patients required blood transfusions. After a 
median follow-up of 5 months (1-15) there had been I heart failure death. 
None of the sundvors had angina symptoms, and median NYHA heart failure 
class was I (~ to III). Sh.~rt term L'se of the pereuteneous Hemopump in the 
catheterization ~aberatory is associated with only very limited compticatione. 
It effectively supports the systemic irculation and thus appears to increase 
the safety of high dsk PTCA procedu,as. 
~ Effects of cardlomyoplssty on Right Ventdcular 
Diastolic Filling During Volume Loading 
Yoshiya Toyoda, Masayoshi Okada, Mohammed A. Kashem, 
Takuro Tsukube, Tomdichire Mukal. Kobe University School of Medicine, 
Kobe, Japan 
Dynamic cardiomyoplasty (CMP) is currently under investigation. Although 
some clinical and experimental studies have dernonstra~ed improved ven- 
tricular systolic function, CMP may impair ventdcular diastolic function by its 
pericardial constraint. Perioardiai influences are more pronounced in the right 
ventriole as compared with the left ventricle, and volume loading is useful 
for demenstrating the presence of right ventricutar diastolic dysfunction. The 
puq0osa of this study is to evaluate the effects of CMP on dght ventricolar 
diastolic filling during volume loading. Ten adult mongrel dogs weighing 10.9 
.-E 2.4 kg were used in this study. Five dogs were in control group. Rve dogs 
underwent left posterior CMP which was left unstimulated for 2 weeks, and 
followed by chronic stimulation for 8 w~eks. The effects of unstimulated CMP 
on hemodynamius were evaluated by heart catheterization with a Swen-Ganz 
catheter during volume loading (central intravenous infusion of 10 ml/kg of a 
4.5% albumin solution). Cardiac output, LVP, AOP, RVP, PAP, LVEF, RVEF 
was increesed and RVEDP was decreased significantly when con~ared be- 
twean the oardiomyostimulator on and off. After volume loading in contrdi, 
RAP and RVEDP were unohonged, but RVEDV was Increased signiticantly. 
In chmntc adynamic CMP, RAP and RVEDP were increased significantly, but 
RVEDV was not significantly increased. 
Hemedynamics before and after velume loading were as follows: 
RAP RVEDP RVEDV PAP CO 
Conlrol: before 3.64-0.9 2.64-2.1 424-12 30±6.1 2.584-1.3 
after 4.04-1.4 3.2:E 1.3 62-1-22, 37 ~: 5.7" 4.07 ± 1.9" 
CMP: before 3.0:1:1.4 4.24-2.2 554-10 31 ±4.7 2.674-0.3 
alter 6.24-2.3 ° 10±23" 644-6.2 35±2.8 3.25~:0.9 
*p < 0.05 Vs Before. ANOVA 
[Conclusion] CMP may impair the dght ventricular diastolic filling by its 
pericardial constraint during volume loading. 
~ Protelnass Inhibitor Complexes In Cardiogenic 
and Septic Shock 
Ralnhard C. Funck, Wemer Cassel, Helner Blanke, Rainer Seifz, 
Rudolf Egbdng, Bernhard Malsch. D~ of C, ardiology, U. of Marburg, FRG 
In patients (pts) with shock, reduced left ventdcular function and fever it may 
be difficult o exclude septicemia. Therefore we determined the plasma levels 
of the protelnase inhibitor complexes elastase-a 1 proteioane-inh~ltor (ELPI) 
and thrombin-antlthrombio if  (TAT) in 34 pts with cardtoganic shock (CAS) 
and 15 pts with septic shock (SES). 
Methods: ELPI and TAT levels were measuraddudng 4 days after onset 
of 31~ck. Values above the empirically found threshold of 700 pg/I were 
considered to be specific for SES. 
Resu~: ELPI was significantly higher (p < 0,001) in SES (table). Based 
on the 700/zg/I ELPI threshold sensitivity was 0.9C6 in CAS and 0.917 in 
SES. Specificity was 0.917 in CAS and 0.966 in SES. 
Mean ELPI Levels and 95%-confldence Intervals* 
TAOS C AS SES 
4-12 h 411.0 :t: 344.4 pg/l 2384.0:1:444.7 ~g/l' 
12-~4 h 373.4 ~ 356.5 pg/1 1746.5 :b 471.6 ;zg/I 
24--48 h 297.1 =b 385.1/zO/I 1983.4 ~ 421.9 pg/I 
TAOS - time after onset of shock, *normal value: < 200 pg/I 
Conclusion: The : ~-rmination of EI.PI is a nonlnvesive and effective way 
to discriminate CAS and SES. Pts. with ELPI concerttrations > 700 pg/~ are 
YeW likely to suffer from septtcomla. Sensitivity and specificity are excellent. 
TAT levels do not con~bute to the discrimination of CAS and SES, 
~ T h e  Quantitative Analysis of the Coronary 
Perfusion Dudng PTCA With an Astive Perfusion 
selloc~z System 
H~ns R. Flgulla, Markus Ferrari, Jens Wicke, Heindch Krsuzer. Dept. of 
Cardiology, Univers~ of C-~ngen, Germany 
Balloon occlusion of large coronary vessels during PTCA may result in pump 
failure, predominantly in patients with impaired LV-function. To prevent pump 
failure, coronanj assist devices, such as eutoperfusion catheters or low 
profile active pa,'fusion catheters (Corftow TM, Leocor) can be used. Since 
the flow rate of autoperfusion catheter is only 30-50 ml/min and dependent 
on the coronary pressure gradient-- the latter might decrease during PTCA 
in high risk patients - -  a pressure independent active perfus~ons ystem 
might be superior. However, the ques~on mm, a!ne, whether this system is 
able to provide at feast the coronary flow rate during balloon occlusion, that 
can be measured prior to balloon occlusion. In 12 patients with coronary 
vessels supplying lanje amount of myocardium the comnan/flow velocity 
was measured ~ a 0.014" doppler guide wire (RoWe TM) prior to and 
during PTCA with an active parfusion system in the poststenotic vessel The 
coronary flow rote (= average peak flow velocity/2 x vessel uminal area) was 
42.2 ~ 5.1 mVmin prior to PTCA, and during balloon occlusion 55.4:1:19.6 
mVmin. The correlation between the external pump rate and the measured in 
situ values were satisfying (r = 0.91 ). In 11 of 12 pts the poststenotic coronary 
flow rate during balloon occlusion could be adapted to the pre-PTCA vaiue.~. 
The results indc, ate that during PTCA of high risk patients a sufficient 
coronan] perfusion rate can be maintained in the distal vessel with an active 
perfusion system. Thus, this toot reliably provides enough coronary flow to 
prevent pump failure in high risk patients. 
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~ B o n e  Loss in Cardiac Cachectic CHF Patients 
Stefan D. Anker, Tuan Peng Choa, Derek Harrington, Belinda Lees, 
Wolfgang Kox 1, John Stevenson, Philip A. Pcole-Wilsen, Andrew 
J.S. Coats. Irnperlal College and Royal emmpton Hospital, London, UK; 
1 Charitd Bedin, Germany 
Cardiac cachaxla is charactedsed by muscle atrophy. In previous work we 
found the crass-sec~on~l area of the femur in cachectic [c] compared with 
non-cachectic [nc] chronic heart failure [CHF] patients also to be reduced. 
We thereiom assessed total bone mineral deush'y [BMD] and bone miner~ 
content [BMC] by means of dual-energy x-ray absorptiometry in36 noCHF 
(age 59,2 -I- 1.3 y, height 173 -4- 1 cm, mean -~ SE) and 17 cCHF patients 
(62.6:1:2.6 y, 172 :E 1 cm, beth p = NS). Both groups had aimifar MVO= (15.6 
± 1.6 vs 17.2 :t: 1.0 ml/kg/min), LVEF and NYHA class. The cCHF patients 
were grossly almph, ic (all weight loss > 5 kg, body mass index < 24 kg/n~, 
81 ± 2 vs 105:1:2 % ideal weight, p < 0.0001). 
BMD (1.16 :1: 0o02 ~s 1.28 • 0.01 g/cm2, p = 0.01) aad BMC (2677:1:63 vs 
3114:1:58 g, p < 0.0001) were reduced in cCHR BMC was equally reduced 
in arms, legs and trunk of cCHF (all p < 0.001). Overall the reduced BMD 
was correlated with the degree of atrophy (%ideal body weight, r = 0.44, p = 
0.001), serum pllosphate (r = -0.34), TNF-= (r = -0.28) and age (r = -0.28, 
all p < 0.05). The absoluLe loss of bone (BMC) correlated with phosphate 
and TNF-a (both r = -0.34, p = 0.015), cor6sot (r = -0.38) and femoral 
cress-sectional reas (all p < 0.05), but not with age. BMC and BMD were 
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We corctude that cardiac cacbexta is chamctarised by a marked absolute 
bone loss and a reduction of bone der~ily, possibly taadlng to increased 
fracture risk. Taking % Ideal body weight as a measure of atrophy, humora! 
catabolic factors such as TNF-a and cortisol (and possibly ethere) contribute 
partly to reduced bone mineral density. 
~ '~- -~ Vitsmin O Deficiency Is Common in Heart Failure 
Donna Mmctnt, Kefih Aareneon, Ann Foray, vicki A(~lresso, Stuart Katz, 
Elizabeth Shone. Columbia-Prebyterian Medical Center, NY, IVY 
Calcitrol (CT), the active matsbollte of Vitamin D 0tit 13) produced by the 
kidney, regulates plasma calcium (Ca) by its actions at bone, kidney end 
intestine. Recently other actions of CT have been described including rapid, 
non-genomlo activation of Ca channels in "nontmditionat" tissues. In vascular 
smco~ muscle, CT incr_~sen ~cell g ro~ and the contractile respo,-.~e to 
noreptnephfine, tn the heart, low CT has been associated with impaired 
mitochreoddal oxidative posphorylation, decreased contrantilily, and increase 
hypertrophy. V'it D status can be assessed by meast, dng soum CT or Calcidiol 
(CD, the storage form of Vit D). To evaluate Vii D status in CHF, serum CT, 
CD, parathyroid hormone (PTH), Ca, PO4, BUN, crealinine (Cr), 24 hr udnary 
Ca and Cr were measured in 84 patients. Hemedynamlo measurements, 
LVEF, peak VO2, pdodty status at transplant were also measured. The 11 
patlonts with low CD levels were more likely to be Status I (13 < 0.02), 
had lower peak VO2 (12.5 :E 3.7 vs 7.4 ± 4.9 ml/kg]mfn;p < 0.05), lower 
serum Ca (9,6 :E 0.1 vs 8.8 • 0.2 mg/dl; p < 0,001) and tendency to 
higher mean pulmonary artery pressures, The 22 patients with low CT levels 
had a significant reduction in crealinine clearance (60 :E 21 vs 39 :l: 22 
ml/min;p < 0.00!) and serum Ca (9,6 -4- 0.1 vs 9.3 :E 0.2; p < 0.05). Only 
4 paUents had Significantly reduced CD and CT levels. High PTH levels 
(> 65 pg/ml), present in 25 patients, did not correlate with renal function 
or Vii D levels. LVEF was s'~gar in low Vit D and high PTH groups, lo 
conclusion, Vit D deficiency is a common finding in patients with CHE CD 
deficiency correlates with the severity of the disease and is probably related 
to combination of dietary factors, malabsorption and low sunlight exposure. 
CT deficiency is closely associated with renal insufficiency. Though major 
hemodynemie differences were not found between ormal and Vit 13 deficient 
patients, further investigstion is warranted to determine if Vit D administration 
has therapeutic benefit in this patient population. 
~"~ High Circulating Levels of  Cardiac Tfoponin I in 
Human Congeative Heart Failure 
Emile Missov, Chadas Calzolari 1 Bernard Pau 2. Department of Cardiology, 
Ueiversity Hospital, Montpellier, France; 1 Sanofi Recherche, Montpeltier, 
France; 2 CNRS UMR 9921, Montt~llier, France 
Neuro-endecdne and immune dysfunction have been extensively reported in 
congestive heart failure (CHF) patients, However, the biochemical diagnosis 
of CHF lacks specificity. Cardiac troponin I (cTnl) is a regulatory protein 
uniquely located in the myocardium with 31 additional amino acid residues 
at the N-terminal and more than 40% dissimilarity with the skeletal muscle 
Isoforms. in the present study, we postulated that end-stage CHF patients 
would have high cimutating levels of cTnl. Sere from 11 male end-stage CHF 
ps~isnts (mean age 46 :t: 11 years, mean LV ejection fraction 19.3 :E 5.9%), 
and from 11 healthy control subjects were assessed for cTnt using a highly 
specific slngis-alep immunoenzymomaldc assay without crossreactivity with 
the skeletal muscle isoforms (cut-off value 10 pg/mL, detection limit 3 pg/mL), 
High circulating levels of cTnt were found In all but one CHF patients. The 
median (25th, 75th percentile) serum cTni was 32 (15, 55) pg/mL, mean (SD) 
89 (166) WmL in CHF patients and belOw the detection limit of the assay 
in control subjects 0 (0, 5) pg/mL, mean (SD.) 2.9 (3.8) pg/mL, p = 0.gg0t. 
Furthermore, oTnl was strongly associated with LV eje~on fraction in CHF 
patients (R = -0.70, p = 0.01): the higher the cTnl levels, the lower the 
ejection fraction. This study provides the first evidence for elevated serum 
cTnl in human end-ctage CHF. cTn[ is a reliable cardiac-specific marker 
molecule that could be used for screening and risk-assessment in CHF 
patients. 
~- '~ Evaluation of  Magnitude of  Effect and Si,t;e of  
Action of Oopamine on the Renal Circula,~ion in 
Patients With Heart Fellure With the Aid of 
Intravescuiar Ultrasound and Doppler Techniquee 
Ud Elkeyam, Sameh Gedallah, Anilkumar Mehra, Rejendra Vallabhaneni, 
Janet V. Johnson. USC SchoM o/ Medicine, Los Angeles, CA 
Although "renal dose* dopamine is often used to increeso renal blood flow 
(RBF), data on magnitude of effect and sits of action are scarce. We evaluated 
the renal effect of intravenous dopamlne in doses of 1, 2, 3, 5 and 10 
mcg/kg/mln in 11 pts with chronic heart failure (CHF) undergoing cardiac 
catheterization. Effect on mean renal artedat pressure (RAP), renal artery 
cross sectional area (CSA), renal vascular resistance (RVR) and F'=JF were 
assessed. CSA was measured by intravascular ultrasound and renal artery 
flow velocity by intravascular Doppler, The effects were as follows: 
FlAP CSA RVR RBF 
(mmHg) (cm 2) (dynes) (ml/min) 
Baseline 95 ± 5 0.256 :E 0.02 16243 ±1861 475 ± 64 
1 mcg~min 93:~5 0.268 ~: 0.02 13248 ±t796" 608±98 
2 mcg/kg/m|n 93±6 0.285 • 0.02 11785±1728" 711:~141 
3 mcg/kg/mtn 96 :t: 5 0.290 ± 0.02 10218 =t: 1362" 74e :E 70* 
5 mcg/kg/mln 100 ± 4 0.299 ~: 0.02 9359 .+. 1385* 8764- 99' 
10 mcg/kg/mln 1024-11 0,268 d: 0.0A 10014±1996' 765:1:133" 
• p < 0.05 vs baseline 
Conclusions: 1) Dopamlne at 3-10 mng]kg/min results in a significant 
augmentstion of RBF in pts with CHF with a maximum effect of 108 :E 30% 
at 8 mcg/kg/min; 2) marked increase in RBF in spite of only a small and 
statistically insignificant increase in CSA suggest dilation of renal resistance 
vessels as a predominant site of dopamine effect on the renal circulation, 
~ Cacmoxirole, a Novel Selective DAe-Receptor 
Agoniat, Acutely Reduces Neurohormonal  
Activation and Improves Cardiac Function in 
Moderate to Severe Heart Failure 
Martin van der Ent, Ad F.M. van den Heuvel, Wlitem J. Remme. Sticares 
Foundation, Rotterdam, The Nethedands 
In heart failure therapy, one of the novel approaches concerns further modu- 
lation of neurohormonal ctivation in addition to ACE inhibition. EMD 45609 
(carmoxireta, C), a DAe-recepter agonist with limited central activity, modu- 
lates sympathetic activation and subsequently reduces pro- and afterloed. 
As the effect of a specific DAe-agnnist has not been studied yet in heart 
failure patients, the effect of C on neumhermones and hemodynamics was 
evaluated in 12 normotsnsive patients with NYHA cl Ill-IV heart failure on sta- 
ble ACE-inhibitor and diuretic therapy. C (0.25-1.00 rag) was administered 
on 2 consecutive days, and hemodynamio and neumhormunal measure- 
men~ carded out, Values given am maximal % changes ,'ram baseline (p 
< 0.05). The lower dose on day I (0.25-0.50 rag) reduced circulating nore- 
pinephdne, vesOpressin and ANF by 40%, 19°/,, and 25%, rasp. In addition, 
on day 2, at a dose level of 0.75-1.00 rag, plasma renin activity decreased 
by 30%. Changes in other neurohormones were comparable to day 1. C 
dose-dependenhy reduced mean arterial pressure and systemic resistance 
by 10% and 18%, rasp. Pulmonary wedge and dght atrial pressure fell by 
38% and 39"/=, rasp. Cardiac pump function improved with a maximal 20% 
inorease in cardiac index. Despite a concomitant 12=/o reduction in heart rate, 
both stroke volume and stroke work increased by 32% and 31%, rasp. Mean 
pulmonary artery pressure decreased by 21%. Thus, C significantly modu- 
lates sympathetic activation already at a low dose, accompanied by changes 
in vasopressin and ANF, and, at the high dose, in the renin-angiotansin sys- 
tem. These effects lead to a reduction in systemic vascular resistance and 
heart rate, and to an improvement inca:dies pump function and left and dght 
ventdcular filling pressures, already at the lowest dose level. It is concluded 
that selective DA~ agonists such as carmokirele may be a useful addition to 
heart failure treatment through their neurohormona! modulating effects. 
~ Aldosterene in Syndromes of  Untreated 
Congestive Heart Failure 
lnder S. Anand, Y. Chandrashekhar, Roberto Ferrad, Philip Poota-Wlison, 
Peter Herds. VA Medical Center, Minneapolis, MN; National Heart & Lung 
Institute, London, UK 
Serum aldosterone is elevated in some patients with congestive heart failure 
(CHF) but its role in the pathogenesis of CHF is unclear, Aldostemne causes 
sodium retention, stimulates fibrous tissue proliferation in the heart after 
myocardial infarction and may, therefore, influence the natural history of 
heart failure. Aldosterone levels are also known to be significantly altered 
by drugs used in the treatment of CHR In view of this, we moesured and 
correlated serum aldosterone levels with hemodynamios, plasma hormones 
[norepinephrine, plasma renin activity (PRA) & ANF], total body water (TBW), 
total body exchangeable sodium (TBNa) and effective renal plasma flow 
(ERPF) In untreated patients with different syndromes of CHF: Low output 
heart failure due to systolic dysfunction (untreated ilated cerdlomyopathy, n 
= 7) & diastolic dysfunction (untreated constrictive pericarditis, n = 15), and 
high output failure (chronic or pulmonale, n = 9). Aldosterene was markedly 
irmreased in patients with untreated low output systolic CHF (330 =t: 122 
pg/ml, normal 52 :t: 7 pg/ml, p = 0,02) and correlated strongly with PRA (r 
= 0.87, p < 0.01) but not with other hormones, hemodynamics, TBW, TBNa 
or ERPR In patients with low output diastolic heart failure, aldosterone was 
moderately elevated (178 ± 42 pg/ml, p = 0.003) & correlated with PRA (r = 
